P/E ratio for Revance Therapeutics (RVNC)
P/E ratio as of May 2024 (TTM): -0.7329
According to Revance Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.732892. At the end of 2022 the company had a P/E ratio of -3.84.
P/E ratio history for Revance Therapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.84 | -1.7% |
| 2021 | -3.90 | -33.18% |
| 2020 | -5.84 | 31.77% |
| 2019 | -4.43 | -13.21% |
| 2018 | -5.11 | -42.98% |
| 2017 | -8.96 | 37.64% |
| 2016 | -6.51 | -42.83% |
| 2015 | -11.4 | 156.77% |
| 2014 | -4.43 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -1,552.19% | 🇺🇸 USA |
 Biogen BIIB | 12.0 | -1,737.20% | 🇺🇸 USA |
 MediciNova MNOV | -6.12 | 735.05% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.